Logo image of SANA

SANA BIOTECHNOLOGY INC (SANA) Stock Fundamental Analysis

NASDAQ:SANA - Nasdaq - US7995661045 - Common Stock - Currency: USD

3  +0.03 (+1.01%)

After market: 3.03 +0.03 (+1%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SANA. SANA was compared to 551 industry peers in the Biotechnology industry. SANA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SANA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SANA had negative earnings in the past year.
In the past year SANA has reported a negative cash flow from operations.
In the past 5 years SANA always reported negative net income.
In the past 5 years SANA always reported negative operating cash flow.
SANA Yearly Net Income VS EBIT VS OCF VS FCFSANA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -46.84%, SANA perfoms like the industry average, outperforming 51.36% of the companies in the same industry.
With a Return On Equity value of -99.81%, SANA perfoms like the industry average, outperforming 45.37% of the companies in the same industry.
Industry RankSector Rank
ROA -46.84%
ROE -99.81%
ROIC N/A
ROA(3y)-45.37%
ROA(5y)-41.34%
ROE(3y)-86.33%
ROE(5y)-74.79%
ROIC(3y)N/A
ROIC(5y)N/A
SANA Yearly ROA, ROE, ROICSANA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

SANA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SANA Yearly Profit, Operating, Gross MarginsSANA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for SANA has been increased compared to 1 year ago.
The number of shares outstanding for SANA has been increased compared to 5 years ago.
There is no outstanding debt for SANA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SANA Yearly Shares OutstandingSANA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
SANA Yearly Total Debt VS Total AssetsSANA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

SANA has an Altman-Z score of -4.82. This is a bad value and indicates that SANA is not financially healthy and even has some risk of bankruptcy.
SANA's Altman-Z score of -4.82 is in line compared to the rest of the industry. SANA outperforms 40.47% of its industry peers.
There is no outstanding debt for SANA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.82
ROIC/WACCN/A
WACCN/A
SANA Yearly LT Debt VS Equity VS FCFSANA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 3.40 indicates that SANA has no problem at all paying its short term obligations.
The Current ratio of SANA (3.40) is comparable to the rest of the industry.
A Quick Ratio of 3.40 indicates that SANA has no problem at all paying its short term obligations.
SANA has a Quick ratio (3.40) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.4
Quick Ratio 3.4
SANA Yearly Current Assets VS Current LiabilitesSANA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

SANA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.14%, which is quite impressive.
EPS 1Y (TTM)40.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 6.45% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y32.61%
EPS Next 2Y16.28%
EPS Next 3Y9.31%
EPS Next 5Y6.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SANA Yearly Revenue VS EstimatesSANA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2032 50M 100M 150M
SANA Yearly EPS VS EstimatesSANA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SANA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SANA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SANA Price Earnings VS Forward Price EarningsSANA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SANA Per share dataSANA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.28%
EPS Next 3Y9.31%

More info and screens

0

5. Dividend

5.1 Amount

SANA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SANA BIOTECHNOLOGY INC

NASDAQ:SANA (8/8/2025, 8:05:43 PM)

After market: 3.03 +0.03 (+1%)

3

+0.03 (+1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-06 2025-11-06/amc
Inst Owners89.23%
Inst Owner Change0.18%
Ins Owners8.27%
Ins Owner Change0.34%
Market Cap676.68M
Analysts84.29
Price Target9.52 (217.33%)
Short Float %16.96%
Short Ratio6.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.68%
Min EPS beat(2)9.03%
Max EPS beat(2)10.32%
EPS beat(4)4
Avg EPS beat(4)12.24%
Min EPS beat(4)1.83%
Max EPS beat(4)27.76%
EPS beat(8)5
Avg EPS beat(8)7.62%
EPS beat(12)9
Avg EPS beat(12)11.29%
EPS beat(16)12
Avg EPS beat(16)10.69%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.66%
EPS NY rev (1m)0%
EPS NY rev (3m)14.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.24
P/tB 73.1
EV/EBITDA N/A
EPS(TTM)-0.88
EYN/A
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.91
OCFYN/A
SpS0
BVpS0.93
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.84%
ROE -99.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.37%
ROA(5y)-41.34%
ROE(3y)-86.33%
ROE(5y)-74.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 102.47%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.4
Quick Ratio 3.4
Altman-Z -4.82
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)135.8%
Cap/Depr(5y)216.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
EPS Next Y32.61%
EPS Next 2Y16.28%
EPS Next 3Y9.31%
EPS Next 5Y6.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.69%
EBIT Next 3Y4.5%
EBIT Next 5YN/A
FCF growth 1Y27.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.3%
OCF growth 3YN/A
OCF growth 5YN/A